JP2014240402A5 - - Google Patents

Download PDF

Info

Publication number
JP2014240402A5
JP2014240402A5 JP2014152732A JP2014152732A JP2014240402A5 JP 2014240402 A5 JP2014240402 A5 JP 2014240402A5 JP 2014152732 A JP2014152732 A JP 2014152732A JP 2014152732 A JP2014152732 A JP 2014152732A JP 2014240402 A5 JP2014240402 A5 JP 2014240402A5
Authority
JP
Japan
Prior art keywords
iodophenyl
bromophenyl
fluorophenyl
chlorophenyl
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014152732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014240402A (ja
JP5837657B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014240402A publication Critical patent/JP2014240402A/ja
Publication of JP2014240402A5 publication Critical patent/JP2014240402A5/ja
Application granted granted Critical
Publication of JP5837657B2 publication Critical patent/JP5837657B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2014152732A 2004-11-10 2014-07-28 糖尿病の処置方法 Expired - Fee Related JP5837657B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62644804P 2004-11-10 2004-11-10
US60/626,448 2004-11-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012225142A Division JP2013032377A (ja) 2004-11-10 2012-10-10 糖尿病の処置方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134366A Division JP2015193638A (ja) 2004-11-10 2015-07-03 糖尿病の処置方法

Publications (3)

Publication Number Publication Date
JP2014240402A JP2014240402A (ja) 2014-12-25
JP2014240402A5 true JP2014240402A5 (enExample) 2015-06-25
JP5837657B2 JP5837657B2 (ja) 2015-12-24

Family

ID=35965895

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007541294A Withdrawn JP2008519840A (ja) 2004-11-10 2005-11-09 糖尿病の処置方法
JP2012225142A Pending JP2013032377A (ja) 2004-11-10 2012-10-10 糖尿病の処置方法
JP2014152732A Expired - Fee Related JP5837657B2 (ja) 2004-11-10 2014-07-28 糖尿病の処置方法
JP2015134366A Pending JP2015193638A (ja) 2004-11-10 2015-07-03 糖尿病の処置方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007541294A Withdrawn JP2008519840A (ja) 2004-11-10 2005-11-09 糖尿病の処置方法
JP2012225142A Pending JP2013032377A (ja) 2004-11-10 2012-10-10 糖尿病の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015134366A Pending JP2015193638A (ja) 2004-11-10 2015-07-03 糖尿病の処置方法

Country Status (6)

Country Link
US (3) US8003617B2 (enExample)
EP (1) EP1811991B1 (enExample)
JP (4) JP2008519840A (enExample)
BR (1) BRPI0517701A8 (enExample)
CA (1) CA2586761A1 (enExample)
WO (1) WO2006053043A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
WO2007134086A2 (en) 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
US20100048714A1 (en) * 2006-06-19 2010-02-25 University Of Utah Research Foundation Methods and Compositions Related to Inhibition of Ceramide Synthesis
EP2594562B1 (en) 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR101640263B1 (ko) 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
JP2011529500A (ja) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
SG10201407881WA (en) * 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
CN103917094B (zh) 2011-03-18 2016-11-09 建新公司 葡萄糖基神经酰胺合酶抑制剂
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
TW201900625A (zh) 2013-03-15 2019-01-01 美商健臻公司 製備葡糖基神經醯胺合成酶抑制劑之方法
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
AU2014321397C1 (en) * 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
CN105849102B (zh) * 2013-10-29 2020-10-16 生物马林药物股份有限公司 作为葡萄糖基神经酰胺合酶抑制剂的n-(1-羟基-3(吡咯烷基)丙烷-2-基)吡咯烷-3-甲酰胺衍生物
US9758044B2 (en) * 2014-10-02 2017-09-12 Ford Global Technologies, Llc Bus leakage resistance estimation for electrical isolation testing and diagnostics
KR101711706B1 (ko) * 2014-11-20 2017-03-02 주식회사 엘지화학 공통 모드 노이즈 시뮬레이터
EP3268355B1 (en) 2015-03-11 2019-06-12 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US12527776B2 (en) 2019-02-04 2026-01-20 Genzyme Corporation Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS)
US20230002380A1 (en) 2019-11-15 2023-01-05 Yuhan Corporation Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
BR112022009409A2 (pt) 2019-11-15 2022-08-09 Yuhan Corp Novos derivados que têm grupamento 2,3-dihidro-1h-indeno ou 2,3-dihidrobenzofurano ou sal farmaceuticamente aceitável dos mesmos e composições farmacêuticas que os compreendem
EP4100009A1 (en) 2020-02-03 2022-12-14 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) * 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) * 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
EP0144290A3 (de) 1983-12-01 1987-05-27 Ciba-Geigy Ag Substituierte Aethylendiaminderivate
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) * 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
EP1008342A3 (en) * 1994-02-02 2004-12-29 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
WO1995034530A1 (en) * 1994-06-10 1995-12-21 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
US5916911A (en) * 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6222619B1 (en) * 1997-09-18 2001-04-24 University Of Utah Research Foundation Diagnostic device and method
US6465488B1 (en) * 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
EP1098642B1 (en) * 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
MXPA02000296A (es) * 1999-07-09 2004-05-21 Univ Michigan Compuestos parecidos a aminoceramida y metodos de uso.
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
JP5009459B2 (ja) 1999-12-06 2012-08-22 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
US6235737B1 (en) * 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
AR028023A1 (es) 2000-04-19 2003-04-23 Borody Thomas J Una composicion farmaceutica para el tratamiento de la hiperlipidemia y el uso de dicha composicion para la preparacion de medicamentos
CA2432908A1 (en) 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Company Diamines as modulators of chemokine receptor activity
CA2431679A1 (en) 2000-12-29 2002-07-11 Wyeth Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines
US20040260099A1 (en) * 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
PT2266968E (pt) * 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
JPWO2003057874A1 (ja) * 2001-12-28 2005-05-19 住友製薬株式会社 腎疾患の疾患マーカー及びその利用
ATE314370T1 (de) 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
EP1336411A1 (en) 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
JP2003238410A (ja) 2002-02-21 2003-08-27 Seibutsu Yuki Kagaku Kenkyusho:Kk インスリン抵抗性解除剤
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
BR0312947A (pt) 2002-07-17 2007-07-10 Biogen Idec Inc terapias para insuficiência renal empregando-se interferon-beta
US7985760B2 (en) * 2002-07-17 2011-07-26 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosyceramid synthase
WO2004078194A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
GB0313678D0 (en) * 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005039578A2 (en) 2003-10-29 2005-05-06 Macrozyme B.V. Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
US20070270350A1 (en) 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
ATE500752T1 (de) * 2004-03-16 2011-03-15 Tno Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
EP1576894A1 (en) * 2004-03-16 2005-09-21 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
US20070224200A1 (en) 2004-05-07 2007-09-27 Samer Elbawab Gm3 Synthase as a Therapeutic Target in Microvascular Complications of Diabetes
WO2005123055A2 (en) 2004-06-14 2005-12-29 Musc Foundation For Research Development Methods for treating inflammatory disorders
CA2581173A1 (en) * 2004-08-20 2006-03-02 The Johns Hopkins University Methods for treatment of angiogenesis
JP2008519840A (ja) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
US20090088433A1 (en) 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2007134086A2 (en) 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
WO2008011478A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法
EP2117541A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2594562B1 (en) * 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR101640263B1 (ko) 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Similar Documents

Publication Publication Date Title
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
JP2008519840A5 (enExample)
JP2017214387A5 (enExample)
JP2010529118A5 (enExample)
JP2007533752A5 (enExample)
JP2017535559A5 (enExample)
JP2006501295A5 (enExample)
RU2017132673A (ru) Производные собетирома
JP2017526727A5 (enExample)
JP2010532386A5 (enExample)
CA2713025A1 (en) Kappa selective opioid receptor antagonist
JP2013006854A5 (enExample)
DK2394645T3 (en) Medical uses of 5-benzylaminosalicylsyrederivater or salts thereof
JP2011246469A5 (enExample)
CY1113622T1 (el) Κρυσταλλικη μορφη μιας ενωσης 4-[2-(2-φθοροφαινοξυμεθυλο)φαινυλο]πιπεριδινης
JP2018522581A5 (enExample)
JP2009540012A5 (enExample)
JP2014503599A5 (enExample)
JP2019151627A5 (enExample)
JP2016510719A5 (enExample)
JP2007515467A5 (enExample)
JP2010504321A5 (enExample)
JP2015536965A5 (enExample)
RU2015110006A (ru) Замещенные соединения цианопиразола в качестве антагонистов лизофосфатидной кислоты
JP2011251968A5 (enExample)